ARCT - Arcturus Therapeutics

-

$undefined

N/A

(N/A)

Arcturus Therapeutics NasdaqGM:ARCT Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Location: 10628 Science Center Drive, San Diego, CA, 92121, United States | Website: https://arcturusrx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

171M

Cash

216.9M

Avg Qtr Burn

-22.33M

Short % of Float

21.67%

Insider Ownership

7.89%

Institutional Own.

92.48%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

BLA

Submission

ARCT-032 Details
Cystic fibrosis, Lung disease, Ornithine transcarbmylase deficiency

Susp. Mover™

Phase 2

Data readout

ARCT-810 Details
Ornithine transcarbmylase deficiency, Urea cycle disorder

Susp. Mover™

Phase 2

Data readout

Phase 1b

Data readout

ARCT-2304 Details
H5N1 avian influenza

Phase 1

Data readout

Failed

Discontinued